Taris

Pipeline: Overview of Bladder Diseases

Around the world, bladder diseases are broadly characterized by high unmet medical need due to a lack of effective therapeutic and delivery options. Oral and systemic treatments are inadequate to address patients’ needs, due to dose-limiting side-effects and insufficient symptom relief. Local treatments of these diseases are hampered by a short course of drug exposure and a need for frequent in-office administration procedures. Continuous local treatment of bladder diseases has the potential to provide both superior management of symptoms and reduced systemic side effects.

With tolerability and retention already proven in patients, the TARIS platform technology represents the first system with the potential to achieve continuous local delivery to the urinary bladder. TARIS is focusing its development efforts in bladder diseases with high unmet need, in which current therapies or systemic treatments have failed. Potential areas include up to 60 million patients in the US alone:

TARIS’ lead program is LiRIS (Lidocaine Releasing Intravesical System), which is in development for the treatment of Interstitial Cystitis (IC). TARIS has initiated a Phase 1B clinical study to evaluate the safety and tolerability of LiRIS in patients suffering from moderate-to-severe IC.

Building on the initial success of LiRIS, TARIS is pursuing development in a number of other bladder diseases. These include opportunities in Ureteral Stent Pain/Voiding Dysfunction, Bladder Cancer and Overactive Bladder.

More Information